Vaccine News and Research

Latest Vaccine News and Research

Scientists create 'all-atom' model of SARS-CoV-2 spike protein

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus disease (COVID-19), an illness that has spread across the globe, infecting more than 9 million people. The novel coronavirus invades cells through "spike proteins," which sticks and binds itself to a host cell.

23 Jun 2020

Single-dose Israeli vaccine candidate protective against SARS-CoV-2

Now, a new Israeli study published on the preprint server bioRxiv in June 2020 reports a new recombinant vaccine expressing the S or spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to be highly protective with a single dose in an animal model. This could be a gamechanger in the fight to contain the outbreak.

23 Jun 2020

Growth, adaptation and neutralization of SARS-CoV-2 with acute-phase serum

One recent study published on the preprint server bioRxiv in June 2020 reports the results of growing and characterizing the virus, as well as the development of neutralizing antibodies in the serum of acutely infected hospitalized patients with COVID-19.

22 Jun 2020

Cardiac care in the era of COVID-19

As Cedars-Sinai expands telehealth and video visits and resumes surgeries, Joanna Chikwe, MD, chair of the Department of Cardiac Surgery at the Smidt Heart Institute, has her focus on one thing: ensuring that patients with heart disease understand it is safe to be seen, and treated, by Cedars-Sinai healthcare teams.

22 Jun 2020

Three vaccine candidates race to combat SARS-CoV-2

As the coronavirus disease (COVID-19) ravages across the globe, scientists are racing to develop an effective vaccine to combat the viral infection. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease has infected nearly 9 million people.

22 Jun 2020

Novel vaccine platform against COVID-19 based on engineered human mesenchymal stem cells

In a recent groundbreaking bioRxiv paper, Chinese researchers describe a novel approach towards coronavirus disease (COVID-19) vaccine design based on engineered human mesenchymal stem cells, with favorable and promising antibody response.

22 Jun 2020

Reassuring news on the Oxford vaccine (AZD1222) against SARS-CoV-2

A new paper from the UK vaccine research group, currently available on the bioRxiv preprint server, reveals that a single dose of ChAdOx1 nCoV-19 (AZD1222) can induce antigen-specific antibody and T cells responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a booster shot additionally enhances antibody production with an increase in neutralizing titers – particularly in pigs.

22 Jun 2020

The role of brain cells in spreading HIV

Dr. Lena Al-Harthi speaks to News-Medical about her research into HIV treatment and the role of brain cells in spreading the HIV virus.

22 Jun 2020

Tumor cell–based vaccine may prevent relapse of mantle cell lymphoma

A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient's own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment.

22 Jun 2020

Researchers produce first fully-glycosylated full-length SARS-CoV-2 spike protein models

The virus SARS coronavirus 2 (SARS-CoV-2) is the known cause of coronavirus disease 2019 (COVID-19). The "spike" or S protein facilitates viral entry into host cells.

22 Jun 2020

Synthetic peptide could be an effective COVID-19 treatment and SARS-CoV-2 vaccine

Ligandal, one of the world’s leading genetic medicine companies, has modeled a synthetic peptide that could be an effective COVID-19 treatment and SARS-CoV-2 vaccine.

22 Jun 2020

A highly sensitive and specific antibody test for COVID-19

A new proof-of-concept study by UK researchers, currently available on the medRxiv* preprint server, describes the development of an enzyme-linked immunosorbent assay that can be used when lower levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific-antibodies are present in serum and saliva samples.

21 Jun 2020

Research explores the biophysical behavior of SARS-CoV-2 nucleocapsid protein

In a groundbreaking paper currently available on the bioRxiv* preprint server, the researchers from the Washington University School of Medicine and Stony Brook University showed how nucleocapsid protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is dynamic, disordered and phase separates with RNA – informing, in turn, the discovery of drugs that disrupt viral packaging.

21 Jun 2020

Promising candidate monoclonal antibodies show "exquisite potency" against SAR-CoV-2

Researchers at Columbia University, Dana-Farber Cancer Institute, and the National Institutes of Health have identified and characterized a range of monoclonal antibodies that potently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

21 Jun 2020

New adjuvant helps induce long-lasting immunity against HIV

Researchers at the Yerkes National Primate Research Center and the Emory Vaccine Center (EVC) are first to show a new adjuvant, 3M-052, helps induce long-lasting immunity against HIV.

20 Jun 2020

MMR vaccine could offer protection against COVID-19

Administering the MMR (measles, mumps, rubella) vaccine could serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection, say a team of experts in this week's mBio, a journal of the American Society for Microbiology.

19 Jun 2020

Viruses can steal genetic signals from hosts to expand their own genomes

Like a scene out of "Invasion of the Body Snatchers," a virus infects a host and converts it into a factory for making more copies of itself.

19 Jun 2020

Human trials to commence using SARS-CoV-2 antibodies from cow's blood

The coronavirus pandemic has sparked a sense of urgency as it actively spreads across the globe. The number of reported cases has now surpassed 8.46 million people, with a death toll of more than 453,000. Scientists and pharmaceutical companies are racing to develop an effective treatment and vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

19 Jun 2020

Mutational targets of SARS-CoV-2 receptor-binding domain for vaccine-antiviral development

The COVID-19 pandemic has spread throughout the whole world within six months, causing millions of infections and hundreds of thousands of deaths. Yet there is no effective vaccine or antiviral to deal with it.

18 Jun 2020

First genome-wide CRISPR screen reveals genes that control SARS-CoV-2 infection

By performing a genome-wide CRISPR screen on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), U.S. researchers identified novel proviral genes and pathways, and highlighted host genes that may regulate coronavirus disease (COVID-19) pathogenesis, as well as revealing potential targets for novel treatment approaches. Their findings are currently available on the bioRxiv* preprint server.

18 Jun 2020